gamma-aminobutyric acid has been researched along with Parkinson Disease in 271 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor." | 8.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| "A search of biomedical literature was completed through MEDLINE and EMBASE (1993-May 2002) to identify all clinical trials pertaining to the use of gabapentin for the treatment of tremor in humans." | 8.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| "A search of biomedical literature was completed through MEDLINE and EMBASE (1993-May 2002) to identify all clinical trials pertaining to the use of gabapentin for the treatment of tremor in humans." | 4.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| "To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor." | 4.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| " In search of novel neuroprotectants, we showed that butyrate (BUT), a short-chain fatty acid, protects against salsolinol (SALS)-induced toxicity in human neuroblastoma-derived SH-SY5Y cells, which are considered an in-vitro model of PD." | 4.31 | Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease. ( Copeland, RL; Csoka, AB; Getachew, B; Manaye, KF; Tizabi, Y, 2023) |
| "We found lower GABA+/creatine in PD with visual hallucinations (0." | 3.88 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "We measured the tremor clinical rating scale score and acquired DASB and Flumazenil PET scans in 10 patients who presented with essential tremor at different stages of clinical severity." | 3.78 | Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. ( Figueiras, FP; Gironell, A; Gispert, JD; Herance, JR; Pagonabarraga, J; Pascual-Sedano, B; Trampal, C, 2012) |
| "Concentrations of putative neuroactive substances glutamate, aspartate, gamma-aminobutyric acid, glycine, proline and ethanolamine were determined in ventricular cerebrospinal fluid collected in patients suffering from Parkinson's disease, pain syndromes or cerebellar tremor." | 3.67 | Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. ( Amsler, U; Cuénod, M; Perschak, H; Siegfried, J; Vischer, A, 1987) |
| "Irritable bowel syndrome is regarded as the prototypic disorder of the brain-gut-microbiota axis that can be responsive to probiotic therapy." | 2.55 | The Microbiome-Gut-Brain Axis in Health and Disease. ( Cryan, JF; Dinan, TG, 2017) |
| "We review occupational Mn-induced parkinsonism and the dynamic modes of Mn transport in biological systems, as well as the detection and pharmacokinetic modeling of Mn trafficking." | 2.52 | Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. ( Aschner, M; Bowman, AB; Kwakye, GF; Mukhopadhyay, S; Paoliello, MM, 2015) |
| "Manganese (Mn) is an essential trace element that is required for maintaining proper function and regulation of numerous biochemical and cellular reactions." | 2.49 | Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle. ( Aschner, M; Sidoryk-Wegrzynowicz, M, 2013) |
| " Despite its essentiality, at excessive levels Mn is toxic to the central nervous system (CNS)." | 2.49 | Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle. ( Aschner, M; Sidoryk-Wegrzynowicz, M, 2013) |
| "Conversely, cataplexy, one of the key symptoms of narcolepsy, is a striking sudden episode of muscle weakness triggered by emotions during wakefulness, and comparable to REM sleep atonia." | 2.47 | The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. ( Clément, O; Fort, P; Gervasoni, D; Léger, L; Luppi, PH; Peyron, C; Salvert, D; Sapin, E, 2011) |
| "Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias." | 2.44 | Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. ( Encarnacion, EV; Hauser, RA, 2008) |
| "Levodopa appears to increase DA output by activating these nonfiring neurons; as a consequence, DA release is increased, but behavioral demand can now overwhelm the system, potentially leading to the inactivation and on/off phenomena." | 2.44 | Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. ( Grace, AA, 2008) |
| "The motor symptoms of Parkinson's disease are associated with abnormal, correlated, low frequency, rhythmic burst activity in the subthalamic nucleus and connected nuclei." | 2.43 | Cellular principles underlying normal and pathological activity in the subthalamic nucleus. ( Atherton, JF; Baufreton, J; Bevan, MD, 2006) |
| "Essential tremor is a common movement disorder in adults that interferes with the performance of functional and social activities." | 2.42 | Essential tremor: diagnosis and treatment. ( Chen, JJ; Swope, DM, 2003) |
| "The mainstay of treatment for Parkinson's disease remains medical therapy." | 2.42 | Future and current surgical therapies in Parkinson's disease. ( Betchen, SA; Kaplitt, M, 2003) |
| "Monosymptomatic rest tremor has recently been shown to be associated with decreased fluorodopa uptake on the positron emission tomography scan suggesting its relationship to Parkinson disease." | 2.42 | Tremor. ( Sethi, KD, 2003) |
| "Parkinson's disease is considered to offer only a limited view of basal ganglia function due to partial striatal depletion of dopamine and the potential involvement of other structures and transmitters in its pathology." | 2.42 | Frontal-striatal circuit functions: context, sequence, and consequence. ( Saint-Cyr, JA, 2003) |
| "Parkinson's disease is a neurodegenerative disorder that manifests clinically with variable degrees of tremor, muscle rigidity, bradykinesia and postural instability." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "Tremor-predominant Parkinson's disease is characterised by prominent tremor of one or more limbs with a relative lack of significant rigidity and bradykinesia." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "Current long-term treatment of Parkinson's disease is inadequate, and improved symptomatic and neuroprotective therapies are needed." | 2.38 | N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. ( Greenamyre, JT; O'Brien, CF, 1991) |
| "The changes found in Parkinson's disease are described." | 2.36 | The biochemistry of the basal ganglia and Parkinson's disease. ( Curzon, G, 1977) |
| "The dichotomy of Parkinson's disease; akinesia with increased tone, and the mirror effects in Huntington's disease; hemiballismus and tardive dyskinesia, hyperkinesia with decreased tone are explained as due to two outputs of the system with an intervening inhibitory neuron which reverses the sign." | 2.36 | The basal ganglia in extrapyramidal dysfunction. ( Barnes, CD, 1983) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Patients with Parkinson's disease (PD) show impaired short-term potentiation (STP) mechanisms in the primary motor cortex (M1)." | 1.91 | Short-term plasticity of the motor cortex compensates for bradykinesia in Parkinson's disease. ( Berardelli, A; Bologna, M; Cannavacciuolo, A; Colella, D; Fabbrini, G; Giangrosso, M; Guerra, A; Paparella, G, 2023) |
| "Using the Parkinson's disease model rat brain, images with left-right differences were obtained for the localization of DA and GABA." | 1.72 | Optimization of the use of Py-Tag for next generation derivatization reagents in imaging mass spectrometry. ( Ikeda, A; Kobayashi, S; Maejima, Y; Shikano, H; Shimomura, K; Taira, S; Terauchi, T; Yokoyama, J, 2022) |
| " Tramadol is safe analgesic but long-term use confirmed to elevate oxidative stress, neuroinflammation, mitochondrial dysfunction, in brain leads to motor deficits." | 1.72 | l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. ( Gupta, GD; Raj, K; Singh, S, 2022) |
| "l-Theanine is an active constituent of green tea which prevents neuronal loss, mitochondrial failure and improves dopamine, gamma-aminobutyric acid (GABA), serotonin levels and in the central nervous system (CNS) via antioxidant, anti-inflammatory, and neuromodulatory properties." | 1.72 | l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. ( Gupta, GD; Raj, K; Singh, S, 2022) |
| "The dopaminergic pathology of Parkinson's disease (PD) impacts circuits involving GABAergic neurons, especially in the brainstem, where the disease manifests early." | 1.62 | Upper brainstem GABA levels in Parkinson's disease. ( Edden, RAE; Gong, T; Mikkelsen, M; Saleh, MG; Song, Y; Wang, G, 2021) |
| "Current pharmacological treatments for Parkinson's disease (PD) are focused on symptomatic relief, but not on disease modification, based on the strong belief that PD is caused by irreversible dopaminergic neuronal death." | 1.56 | Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. ( Cho, IJ; Heo, JY; Huh, SH; Hwang, EM; Hwang, O; Hwang, YJ; Im, H; Jang, BK; Jang, DP; Jeon, SR; Jeong, JY; Jin, BK; Jo, S; Kim, HY; Kim, J; Kim, KI; Kim, S; Kim, Y; Kowall, NW; Kweon, GR; Lee, CJ; Lee, HJ; Lee, J; Lee, JA; Lee, MJ; Lee, SE; Nam, MH; Oh, SJ; Paek, SH; Park, HJ; Park, JH; Park, KD; Ryu, H; Shim, I; Shim, JE; Shin, H; Won, W; Woo, DH; Yoon, HH; Yoon, JH, 2020) |
| "Parkinson's disease is characterized by bradykinesia, rigidity, and tremor." | 1.56 | GABAergic changes in the thalamocortical circuit in Parkinson's disease. ( Cools, R; den Ouden, HEM; Dirkx, MFM; Helmich, RC; Scheenen, TWJ; Toni, I; van Asten, JJA; van Nuland, AJM; Zach, H, 2020) |
| "GABA levels were unaltered by Parkinson's disease, clinical phenotype, or medication." | 1.56 | GABAergic changes in the thalamocortical circuit in Parkinson's disease. ( Cools, R; den Ouden, HEM; Dirkx, MFM; Helmich, RC; Scheenen, TWJ; Toni, I; van Asten, JJA; van Nuland, AJM; Zach, H, 2020) |
| "We found lower GABA+/creatine in PD with visual hallucinations (0." | 1.48 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex." | 1.48 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "Bradykinesia is a prominent phenotype of Parkinson's disease, depression, and other neurological conditions." | 1.43 | Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling. ( Alvarez, VA; Friend, DM; Kaplan, AR; Kravitz, AV; Lemos, JC; Rubinstein, M; Shin, JH, 2016) |
| "L-Dopa continues to be the gold drug in Parkinson's disease (PD) treatment from 1967." | 1.43 | Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease. ( Abarca, J; Cardenas, C; Díaz-Veliz, G; Gysling, K; Herrera, A; Hultenby, K; Inzunza, J; Jaña, F; Mora, S; Muñoz, P; Paris, I; Raisman-Vozari, R; Segura-Aguilar, J; Steinbusch, HW, 2016) |
| "Parkinson's disease is a multifactorial neurodegenerative disorder, characterized by a reduction of dopamine (DA) levels." | 1.40 | Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease. ( Conte, C; Ianni, F; Lisanti, A; Natalini, B; Sardella, R; Scorzoni, S, 2014) |
| "Essential tremor is the most common movement disorder in adults, but its exact etiology and pathophysiology are still not fully understood." | 1.38 | Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. ( Figueiras, FP; Gironell, A; Gispert, JD; Herance, JR; Pagonabarraga, J; Pascual-Sedano, B; Trampal, C, 2012) |
| "Nicotine was given for 10 days in the pretreatment group." | 1.34 | [The protective effect of nicotine on dopaminergic neuron of Parkinson's disease mice]. ( Feng, YH; Li, Y; Peng, Y; Sun, YP; Yu, DQ; Zhang, DM; Zhang, WQ; Zhao, J, 2007) |
| "Nicotine has a protective effect on the dopaminergic neurons in the MPTP-treated mice." | 1.34 | [The protective effect of nicotine on dopaminergic neuron of Parkinson's disease mice]. ( Feng, YH; Li, Y; Peng, Y; Sun, YP; Yu, DQ; Zhang, DM; Zhang, WQ; Zhao, J, 2007) |
| "Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia." | 1.34 | Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. ( Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C, 2007) |
| "Zolpidem is an imidazopyridine agonist with a high affinity on the benzodiazepine site of GABA(A) receptors containing alpha 1 subunit." | 1.34 | Zolpidem modulates GABA(A) receptor function in subthalamic nucleus. ( Chen, L; Fung, KS; Xie, JX; Yung, WH, 2007) |
| " Dose-response studies with 6-hydroxydopamine revealed that the application of 200 microg per animal caused hypokinetic signs (decreased ambulatory activity, increased inactivity, and reduced motor coordination), which paralleled several signs of degeneration of nigrostriatal dopaminergic neurons (dopamine depletion in the caudate-putamen, and decreased mRNA levels for tyrosine hydroxylase and superoxide dismutase-1 and -2 in the substantia nigra)." | 1.33 | Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. ( de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C, 2006) |
| "When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration." | 1.32 | Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent. ( Abercrombie, ED; Cobb, WS, 2003) |
| "The adenosine inhibition was abolished by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist." | 1.31 | Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. ( Aceves, J; Barajas, C; Erlij, D; Florán, B; Florán, L, 2002) |
| " On day 10, the locomotor response to L-dopa was significantly potentiated by chronic administration of idazoxan." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "Treatment of Parkinson's disease with L-dopa is plagued in a majority of patients by dyskinesias." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "gamma-Aminobutyric acid (GABA) was measured in CSF as such and following acid hydrolysis by the ion-exchange/fluorometric method." | 1.27 | Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984) |
| "In patients with Huntington's disease, on administration of isoniazid at 900 mg/day, along with pyridoxine at 100 mg/day, a 4-fold increase of both free (P less than 0." | 1.27 | Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984) |
| " Dosage and duration of drug treatment did not influence striatal or cortical GAD levels." | 1.27 | Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. ( Agid, Y; Dubois, B; Hauw, JJ; Javoy-Agid, F; Monfort, JC, 1985) |
| "Values found in Friedreich's ataxia or Parkinson's disease were not significantly different from those in controls." | 1.27 | Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. ( Agid, Y; Bonnet, AM; De Smet, Y; Grove, J; Saint-Hilaire, MH; Schechter, PJ; Tell, G, 1987) |
| "In the untreated patients with Parkinson's disease, the CSF GABA level was 95 +/- 31 pmole/mL (n = 7) and in those who were treated with levodopa and carbidopa the level was 144 +/- 53 pmole/mL (n = 8)." | 1.26 | Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa. ( Manyam, BV, 1982) |
| "CSF gamma-aminobutyric acid (GABA) levels were reduced in patients with idiopathic Parkinson's disease when compared with age matched controls, but the difference was not significant." | 1.26 | CSF and plasma GABA levels in Parkinson's disease. ( Abbott, RJ; Nahorski, SR; Pye, IF, 1982) |
| "Like the diabetic, the patients with Parkinson's disease may run into problems during long-term treatment." | 1.26 | Success and problems of long-term levodopa therapy in Parkinson's disease. ( Marsden, CD; Parkes, JD, 1977) |
| "Neuropathologically, Huntington's disease is characterized by a profound reduction in neuronal cells originating in the corpus striatum and globus pallidus." | 1.26 | Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. ( Enna, SJ; Stern, LZ; Wastek, GJ; Yamamura, HI, 1977) |
| "compensated stage of Parkinson's disease)." | 1.26 | CNS compensation to dopamine neuron loss in Parkinson's disease. ( Lloyd, KG, 1977) |
| "Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 88 (32.47) | 18.7374 |
| 1990's | 31 (11.44) | 18.2507 |
| 2000's | 74 (27.31) | 29.6817 |
| 2010's | 54 (19.93) | 24.3611 |
| 2020's | 24 (8.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed-Farid, OA | 1 |
| Taha, M | 1 |
| Bakeer, RM | 1 |
| Radwan, OK | 1 |
| Hendawy, HAM | 1 |
| Soliman, AS | 1 |
| Yousef, E | 1 |
| Vinckier, F | 1 |
| Gaillard, R | 1 |
| Taylor, G | 1 |
| Murray, GK | 1 |
| Plaze, M | 1 |
| Bourdillon, P | 1 |
| Perin-Dureau, F | 1 |
| Nam, MH | 2 |
| Sa, M | 1 |
| Ju, YH | 1 |
| Park, MG | 1 |
| Lee, CJ | 2 |
| Shikano, H | 1 |
| Ikeda, A | 1 |
| Maejima, Y | 1 |
| Kobayashi, S | 1 |
| Terauchi, T | 1 |
| Yokoyama, J | 1 |
| Shimomura, K | 1 |
| Taira, S | 1 |
| Delli Pizzi, S | 2 |
| Franciotti, R | 2 |
| Chiacchiaretta, P | 1 |
| Ferretti, A | 2 |
| Edden, RA | 1 |
| Sestieri, C | 1 |
| Russo, M | 1 |
| Sensi, SL | 2 |
| Onofrj, M | 3 |
| Pinheiro Campos, AC | 1 |
| Martinez, RCR | 1 |
| Auada, AVV | 1 |
| Lebrun, I | 1 |
| Fonoff, ET | 1 |
| Hamani, C | 1 |
| Pagano, RL | 1 |
| Xu, J | 2 |
| Li, Y | 2 |
| Zhu, H | 3 |
| Wu, W | 1 |
| Liu, Y | 1 |
| Guo, Y | 2 |
| Guan, W | 2 |
| Liu, C | 2 |
| Ma, C | 2 |
| Guerra, A | 4 |
| D'Onofrio, V | 3 |
| Asci, F | 3 |
| Ferreri, F | 3 |
| Fabbrini, G | 4 |
| Berardelli, A | 4 |
| Bologna, M | 4 |
| Pan, S | 3 |
| Wei, H | 3 |
| Yuan, S | 3 |
| Kong, Y | 3 |
| Yang, H | 3 |
| Zhang, Y | 6 |
| Cui, X | 3 |
| Chen, W | 4 |
| Liu, J | 5 |
| Getachew, B | 1 |
| Csoka, AB | 1 |
| Copeland, RL | 1 |
| Manaye, KF | 1 |
| Tizabi, Y | 1 |
| Wang, Y | 3 |
| Sun, T | 1 |
| Wang, T | 2 |
| Wang, C | 1 |
| Colella, D | 1 |
| Cannavacciuolo, A | 1 |
| Giangrosso, M | 1 |
| Paparella, G | 1 |
| Li, R | 1 |
| Yang, Y | 1 |
| Wu, Z | 1 |
| Wang, L | 1 |
| Tang, G | 1 |
| Yang, J | 1 |
| Datta, I | 1 |
| Mekha, SR | 1 |
| Kaushal, A | 1 |
| Ganapathy, K | 1 |
| Razdan, R | 1 |
| Hörtnagl, H | 1 |
| Pifl, C | 1 |
| Hörtnagl, E | 1 |
| Reiner, A | 1 |
| Sperk, G | 1 |
| van Nuland, AJM | 1 |
| den Ouden, HEM | 1 |
| Zach, H | 1 |
| Dirkx, MFM | 1 |
| van Asten, JJA | 1 |
| Scheenen, TWJ | 1 |
| Toni, I | 2 |
| Cools, R | 1 |
| Helmich, RC | 2 |
| Heo, JY | 1 |
| Yoon, HH | 1 |
| Kim, J | 1 |
| Hwang, YJ | 1 |
| Won, W | 1 |
| Woo, DH | 1 |
| Lee, JA | 1 |
| Park, HJ | 1 |
| Jo, S | 1 |
| Lee, MJ | 1 |
| Kim, S | 1 |
| Shim, JE | 1 |
| Jang, DP | 1 |
| Kim, KI | 1 |
| Huh, SH | 1 |
| Jeong, JY | 1 |
| Kowall, NW | 1 |
| Lee, J | 1 |
| Im, H | 1 |
| Park, JH | 1 |
| Jang, BK | 1 |
| Park, KD | 1 |
| Lee, HJ | 1 |
| Shin, H | 1 |
| Cho, IJ | 1 |
| Hwang, EM | 1 |
| Kim, Y | 1 |
| Kim, HY | 1 |
| Oh, SJ | 1 |
| Lee, SE | 1 |
| Paek, SH | 1 |
| Yoon, JH | 1 |
| Jin, BK | 1 |
| Kweon, GR | 1 |
| Shim, I | 1 |
| Hwang, O | 3 |
| Ryu, H | 1 |
| Jeon, SR | 1 |
| Muñoz, MD | 1 |
| de la Fuente, N | 1 |
| Sánchez-Capelo, A | 1 |
| Zhang, W | 4 |
| Sun, L | 1 |
| Yang, X | 1 |
| Wang, R | 1 |
| Wang, H | 1 |
| Edden, RAE | 4 |
| Zöllner, HJ | 1 |
| Esposito, R | 1 |
| Bubbico, G | 1 |
| Aiello, C | 1 |
| Calvanese, F | 1 |
| Tartaro, A | 1 |
| Bonanni, L | 1 |
| Song, Y | 2 |
| Gong, T | 4 |
| Xiang, Y | 3 |
| Mikkelsen, M | 2 |
| Wang, G | 4 |
| Saleh, MG | 2 |
| Raj, K | 1 |
| Gupta, GD | 1 |
| Singh, S | 1 |
| Radovanovic, L | 1 |
| Petrovic, J | 1 |
| Saponjic, J | 1 |
| Wang, CT | 1 |
| Mao, CJ | 1 |
| Zhang, XQ | 1 |
| Zhang, CY | 1 |
| Lv, DJ | 1 |
| Yang, YP | 1 |
| Xia, KL | 1 |
| Liu, JY | 1 |
| Wang, F | 1 |
| Hu, LF | 1 |
| Xu, GY | 1 |
| Liu, CF | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Cassano, T | 1 |
| Lopalco, A | 1 |
| de Candia, M | 1 |
| Laquintana, V | 1 |
| Lopedota, A | 1 |
| Cutrignelli, A | 1 |
| Perrone, M | 1 |
| Iacobazzi, RM | 1 |
| Bedse, G | 1 |
| Franco, M | 1 |
| Denora, N | 1 |
| Altomare, CD | 1 |
| Videnovic, A | 1 |
| Klerman, EB | 1 |
| Zee, PC | 1 |
| Heckova, E | 1 |
| Považan, M | 1 |
| Strasser, B | 1 |
| Krumpolec, P | 1 |
| Hnilicová, P | 1 |
| Hangel, GJ | 1 |
| Moser, PA | 1 |
| Andronesi, OC | 1 |
| van der Kouwe, AJ | 1 |
| Valkovic, P | 1 |
| Ukropcova, B | 1 |
| Trattnig, S | 1 |
| Bogner, W | 1 |
| Gao, F | 1 |
| Elmaki, EEA | 1 |
| Nkonika, DM | 1 |
| O'Gorman Tuura, RL | 1 |
| Baumann, CR | 1 |
| Baumann-Vogel, H | 1 |
| Jamwal, S | 1 |
| Kumar, P | 1 |
| Chazalon, M | 1 |
| Paredes-Rodriguez, E | 1 |
| Morin, S | 1 |
| Martinez, A | 1 |
| Cristóvão-Ferreira, S | 1 |
| Vaz, S | 1 |
| Sebastiao, A | 1 |
| Panatier, A | 1 |
| Boué-Grabot, E | 1 |
| Miguelez, C | 1 |
| Baufreton, J | 2 |
| Gilbert, GJ | 1 |
| Firbank, MJ | 1 |
| Parikh, J | 1 |
| Murphy, N | 1 |
| Killen, A | 1 |
| Allan, CL | 1 |
| Collerton, D | 1 |
| Blamire, AM | 1 |
| Taylor, JP | 1 |
| Creed, RB | 1 |
| Menalled, L | 1 |
| Casey, B | 1 |
| Dave, KD | 1 |
| Janssens, HB | 1 |
| Veinbergs, I | 1 |
| van der Hart, M | 1 |
| Rassoulpour, A | 1 |
| Goldberg, MS | 1 |
| Stevenson, SA | 1 |
| Ciucci, MR | 1 |
| Kelm-Nelson, CA | 1 |
| Casas, S | 1 |
| Giuliani, F | 1 |
| Cremaschi, F | 1 |
| Yunes, R | 1 |
| Cabrera, R | 1 |
| Kuruvilla, KP | 1 |
| Nandhu, MS | 1 |
| Paul, J | 1 |
| Paulose, CS | 1 |
| Deuschl, G | 1 |
| Bloem, BR | 1 |
| Yuan, YS | 1 |
| Zhou, XJ | 1 |
| Tong, Q | 1 |
| Zhang, L | 2 |
| Qi, ZQ | 1 |
| Ge, S | 1 |
| Zhang, KZ | 1 |
| Pienaar, IS | 1 |
| Elson, JL | 1 |
| Racca, C | 1 |
| Nelson, G | 1 |
| Turnbull, DM | 1 |
| Morris, CM | 1 |
| Li, D | 1 |
| Liu, Q | 1 |
| Jia, D | 1 |
| Dou, D | 1 |
| Wang, X | 4 |
| Kang, T | 1 |
| Sardella, R | 1 |
| Scorzoni, S | 1 |
| Conte, C | 1 |
| Lisanti, A | 1 |
| Ianni, F | 1 |
| Natalini, B | 1 |
| Ferraro, L | 3 |
| Beggiato, S | 2 |
| Borroto-Escuela, DO | 1 |
| Ravani, L | 1 |
| O'Connor, WT | 1 |
| Tomasini, MC | 3 |
| Borelli, AC | 2 |
| Agnati, LF | 3 |
| Antonelli, T | 3 |
| Tanganelli, S | 3 |
| Fuxe, K | 4 |
| Mori, A | 3 |
| Morari, M | 3 |
| Fantin, M | 1 |
| Buchanan, RJ | 1 |
| Gjini, K | 1 |
| Darrow, D | 1 |
| Varga, G | 1 |
| Robinson, JL | 1 |
| Nadasdy, Z | 1 |
| Dharmadhikari, S | 1 |
| Ma, R | 1 |
| Yeh, CL | 1 |
| Stock, AK | 1 |
| Snyder, S | 1 |
| Zauber, SE | 1 |
| Dydak, U | 1 |
| Beste, C | 1 |
| Kwakye, GF | 1 |
| Paoliello, MM | 1 |
| Mukhopadhyay, S | 1 |
| Bowman, AB | 1 |
| Aschner, M | 2 |
| Paolone, G | 1 |
| Brugnoli, A | 1 |
| Arcuri, L | 1 |
| Mercatelli, D | 1 |
| Herrera, A | 1 |
| Muñoz, P | 1 |
| Paris, I | 1 |
| Díaz-Veliz, G | 1 |
| Mora, S | 1 |
| Inzunza, J | 1 |
| Hultenby, K | 1 |
| Cardenas, C | 1 |
| Jaña, F | 1 |
| Raisman-Vozari, R | 1 |
| Gysling, K | 1 |
| Abarca, J | 1 |
| Steinbusch, HW | 1 |
| Segura-Aguilar, J | 1 |
| Yelkenli, İH | 1 |
| Ulupinar, E | 1 |
| Korkmaz, OT | 1 |
| Şener, E | 1 |
| Kuş, G | 1 |
| Filiz, Z | 1 |
| Tunçel, N | 1 |
| Chen, Y | 1 |
| Xiong, M | 1 |
| Dong, Y | 1 |
| Haberman, A | 1 |
| Cao, J | 1 |
| Liu, H | 2 |
| Zhou, W | 1 |
| Zhang, SC | 1 |
| Lemos, JC | 2 |
| Friend, DM | 1 |
| Kaplan, AR | 1 |
| Shin, JH | 1 |
| Rubinstein, M | 1 |
| Kravitz, AV | 1 |
| Alvarez, VA | 1 |
| Viereckel, T | 1 |
| Dumas, S | 1 |
| Smith-Anttila, CJ | 1 |
| Vlcek, B | 1 |
| Bimpisidis, Z | 1 |
| Lagerström, MC | 1 |
| Konradsson-Geuken, Å | 1 |
| Wallén-Mackenzie, Å | 1 |
| Cui, Q | 1 |
| Pitt, JE | 1 |
| Pamukcu, A | 1 |
| Poulin, JF | 1 |
| Mabrouk, OS | 1 |
| Fiske, MP | 1 |
| Fan, IB | 1 |
| Augustine, EC | 1 |
| Young, KA | 1 |
| Kennedy, RT | 1 |
| Awatramani, R | 1 |
| Chan, CS | 2 |
| Barros, AS | 1 |
| Crispim, RYG | 1 |
| Cavalcanti, JU | 1 |
| Souza, RB | 1 |
| Cristino Filho, G | 1 |
| Bezerra, MM | 1 |
| Pinheiro, TFM | 1 |
| de Vasconcelos, SMM | 1 |
| Macêdo, DS | 1 |
| de Barros Viana, GS | 1 |
| Aguiar, LMV | 1 |
| Di Santo, S | 1 |
| Seiler, S | 1 |
| Ducray, AD | 1 |
| Meyer, M | 1 |
| Widmer, HR | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Ponzo, V | 1 |
| Di Lorenzo, F | 1 |
| Brusa, L | 2 |
| Schirinzi, T | 1 |
| Battistini, S | 1 |
| Ricci, C | 1 |
| Sambucci, M | 1 |
| Caltagirone, C | 1 |
| Koch, G | 1 |
| Kitta, T | 1 |
| Matsumoto, M | 1 |
| Tanaka, H | 1 |
| Mitsui, T | 1 |
| Yoshioka, M | 1 |
| Nonomura, K | 1 |
| Ege, F | 1 |
| Koçak, Y | 1 |
| Titiz, AP | 1 |
| Oztürk, SM | 1 |
| Oztürk, S | 1 |
| Ozbakir, S | 1 |
| Grace, AA | 1 |
| Erol, C | 1 |
| Ozben, S | 1 |
| Ozer, F | 1 |
| Cetin, S | 1 |
| Tiras, R | 1 |
| Wang, S | 1 |
| Zhang, QJ | 1 |
| Ali, U | 1 |
| Wu, ZH | 1 |
| Chen, L | 3 |
| Gui, ZH | 1 |
| Hui, YP | 1 |
| Cagnan, H | 1 |
| Meijer, HG | 1 |
| van Gils, SA | 1 |
| Krupa, M | 1 |
| Heida, T | 1 |
| Rudolph, M | 1 |
| Wadman, WJ | 1 |
| Martens, HC | 1 |
| Kim, ST | 1 |
| Kim, EM | 1 |
| Choi, JH | 1 |
| Son, HJ | 1 |
| Ji, IJ | 1 |
| Joh, TH | 1 |
| Chung, SJ | 1 |
| Muramatsu, S | 1 |
| Jia, J | 3 |
| Li, B | 1 |
| Sun, ZL | 2 |
| Yu, F | 2 |
| Wang, XM | 1 |
| Lee, CR | 1 |
| Tepper, JM | 1 |
| Lanoue, AC | 1 |
| Dumitriu, A | 1 |
| Myers, RH | 1 |
| Soghomonian, JJ | 1 |
| Luppi, PH | 1 |
| Clément, O | 1 |
| Sapin, E | 1 |
| Gervasoni, D | 1 |
| Peyron, C | 1 |
| Léger, L | 1 |
| Salvert, D | 1 |
| Fort, P | 1 |
| Yu, DQ | 1 |
| Peng, Y | 1 |
| Feng, YH | 1 |
| Zhang, DM | 1 |
| Zhao, J | 1 |
| Zhang, WQ | 1 |
| Sun, YP | 1 |
| Zhang, XL | 1 |
| Gao, DM | 1 |
| Kang, N | 1 |
| Zhao, L | 1 |
| Stefani, A | 2 |
| Fedele, E | 2 |
| Vitek, J | 1 |
| Pierantozzi, M | 2 |
| Galati, S | 2 |
| Marzetti, F | 1 |
| Peppe, A | 2 |
| Bassi, MS | 1 |
| Bernardi, G | 3 |
| Stanzione, P | 2 |
| Sarbaz, Y | 1 |
| Gharibzadeh, S | 1 |
| Towhidkhah, F | 1 |
| Goulburn, AL | 1 |
| Stanley, EG | 1 |
| Elefanty, AG | 1 |
| Anderson, SA | 1 |
| Emir, UE | 1 |
| Tuite, PJ | 2 |
| Öz, G | 2 |
| Martir, JF | 1 |
| Bozdagi, O | 1 |
| Martinelli, GP | 1 |
| Friedrich, VL | 1 |
| Holstein, GR | 2 |
| Sun, Z | 1 |
| Gong, X | 1 |
| Jia, Y | 1 |
| Deng, J | 1 |
| Gironell, A | 1 |
| Figueiras, FP | 1 |
| Pagonabarraga, J | 1 |
| Herance, JR | 1 |
| Pascual-Sedano, B | 1 |
| Trampal, C | 1 |
| Gispert, JD | 1 |
| Gao, HC | 1 |
| Song, CY | 1 |
| Lin, L | 1 |
| Yan, ZH | 1 |
| Bai, GH | 1 |
| Ye, FQ | 1 |
| Li, XK | 1 |
| Moustafa, AA | 1 |
| Herzallah, MM | 1 |
| Gluck, MA | 1 |
| Sidoryk-Wegrzynowicz, M | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 1 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 1 |
| Florán, B | 1 |
| Barajas, C | 1 |
| Florán, L | 1 |
| Erlij, D | 1 |
| Aceves, J | 1 |
| Cathala, L | 1 |
| Guyon, A | 1 |
| Eugene, D | 1 |
| Paupardin-Tritsch, D | 1 |
| Faulkner, MA | 1 |
| Bertoni, JM | 1 |
| Lenz, TL | 1 |
| Saint-Cyr, JA | 1 |
| Zhou, FM | 1 |
| Wilson, C | 1 |
| Dani, JA | 1 |
| Cobb, WS | 1 |
| Abercrombie, ED | 1 |
| Sethi, KD | 1 |
| Betchen, SA | 1 |
| Kaplitt, M | 1 |
| Valenti, O | 1 |
| Marino, MJ | 1 |
| Wittmann, M | 1 |
| Lis, E | 1 |
| DiLella, AG | 1 |
| Kinney, GG | 1 |
| Conn, PJ | 1 |
| Di Cara, B | 1 |
| Samuel, D | 1 |
| Salin, P | 2 |
| Kerkerian-Le Goff, L | 2 |
| Daszuta, A | 1 |
| Galeffi, F | 1 |
| Bianchi, L | 2 |
| Bolam, JP | 1 |
| Della Corte, L | 1 |
| HIRAKI, K | 1 |
| IRINO, S | 1 |
| ASANO, T | 1 |
| Drapier, S | 1 |
| Damier, P | 1 |
| Chen, JJ | 1 |
| Swope, DM | 1 |
| Jacobsen, K | 1 |
| Hillion, J | 1 |
| Canals, M | 1 |
| Torvinen, M | 1 |
| Tinner-Staines, B | 1 |
| Staines, W | 1 |
| Rosin, D | 1 |
| Terasmaa, A | 1 |
| Popoli, P | 1 |
| Leo, G | 1 |
| Vergoni, V | 1 |
| Lluis, C | 1 |
| Ciruela, F | 1 |
| Franco, R | 1 |
| Ferré, S | 1 |
| Shindou, T | 2 |
| Kase, H | 2 |
| Aoyama, S | 1 |
| Ichimura, M | 1 |
| Ikeda, K | 1 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koga, K | 1 |
| Koike, N | 1 |
| Kurokawa, M | 1 |
| Kuwana, Y | 1 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 1 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shiozaki, S | 1 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 2 |
| Jenner, P | 1 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 2 |
| Chase, TN | 1 |
| Takakusaki, K | 1 |
| Saitoh, K | 1 |
| Harada, H | 1 |
| Okumura, T | 1 |
| Sakamoto, T | 1 |
| Picconi, B | 1 |
| Centonze, D | 1 |
| Rossi, S | 1 |
| Calabresi, P | 1 |
| Korotkova, TM | 1 |
| Ponomarenko, AA | 1 |
| Brown, RE | 1 |
| Haas, HL | 1 |
| Ogura, M | 1 |
| Nakao, N | 1 |
| Nakai, E | 1 |
| Uematsu, Y | 1 |
| Itakura, T | 1 |
| Yung, WH | 3 |
| Berghuis, P | 1 |
| Dobszay, MB | 1 |
| Ibanez, RM | 1 |
| Ernfors, P | 1 |
| Harkany, T | 1 |
| Ishiwari, K | 1 |
| Mingote, S | 1 |
| Correa, M | 1 |
| Trevitt, JT | 1 |
| Carlson, BB | 1 |
| Salamone, JD | 1 |
| Lévesque, JC | 1 |
| Parent, A | 1 |
| Pei, Z | 1 |
| Miller, DS | 1 |
| Wu, X | 1 |
| Block, ML | 1 |
| Wilson, B | 1 |
| Zhou, Y | 1 |
| Hong, JS | 2 |
| Zhang, J | 1 |
| Hallworth, NE | 1 |
| Bevan, MD | 2 |
| Meissner, W | 1 |
| Leblois, A | 1 |
| Hansel, D | 1 |
| Bioulac, B | 1 |
| Gross, CE | 1 |
| Benazzouz, A | 1 |
| Boraud, T | 1 |
| Terpstra, M | 1 |
| Tkác, I | 1 |
| Aia, P | 1 |
| Lowary, J | 1 |
| Gruetter, R | 1 |
| González, S | 1 |
| Scorticati, C | 1 |
| García-Arencibia, M | 1 |
| de Miguel, R | 1 |
| Ramos, JA | 1 |
| Fernández-Ruiz, J | 2 |
| Gonzáles, S | 1 |
| Deogaonkar, A | 1 |
| Deogaonkar, M | 1 |
| Lee, JY | 1 |
| Ebrahim, Z | 1 |
| Schubert, A | 1 |
| Agnati, L | 1 |
| Mazzoni, E | 1 |
| Surmeier, DJ | 2 |
| Raiteri, M | 1 |
| Pepicelli, O | 1 |
| Pisani, A | 1 |
| Gattoni, G | 1 |
| Hainsworth, AH | 1 |
| Mazzone, P | 1 |
| Lee, SY | 1 |
| Moon, Y | 1 |
| Hee Choi, D | 1 |
| Jin Choi, H | 1 |
| Zeevalk, GD | 2 |
| Manzino, L | 1 |
| Sonsalla, PK | 2 |
| Bernard, LP | 1 |
| Di Giovanni, G | 1 |
| Di Matteo, V | 1 |
| Pierucci, M | 1 |
| Benigno, A | 1 |
| Esposito, E | 1 |
| Atherton, JF | 1 |
| Raju, PM | 1 |
| Walker, RW | 1 |
| Lee, MA | 1 |
| Pilc, A | 1 |
| Ossowska, K | 1 |
| Kickler, N | 1 |
| Krack, P | 1 |
| Fraix, V | 1 |
| Lebas, JF | 1 |
| Lamalle, L | 1 |
| Durif, F | 1 |
| Krainik, A | 1 |
| Rémy, C | 1 |
| Segebarth, C | 1 |
| Pollak, P | 1 |
| Xie, JX | 1 |
| Fung, KS | 1 |
| Mela, F | 1 |
| Marti, M | 1 |
| Dekundy, A | 1 |
| Danysz, W | 1 |
| Cenci, MA | 1 |
| Hikosaka, O | 2 |
| Parga, JA | 1 |
| Rodriguez-Pallares, J | 1 |
| Guerra, MJ | 1 |
| Labandeira-Garcia, JL | 1 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Negron, G | 1 |
| Bishop, C | 1 |
| Poujois, A | 1 |
| Vidailhet, M | 1 |
| Trocello, JM | 1 |
| Bourdain, F | 1 |
| Gaymard, B | 1 |
| Rivaud-Péchoux, S | 1 |
| Winckler, T | 1 |
| Encarnacion, EV | 1 |
| Taverna, S | 1 |
| Ilijic, E | 1 |
| Cools, AR | 1 |
| Nishino, N | 1 |
| Hanada, S | 1 |
| Mita, T | 1 |
| Fujiwara, H | 1 |
| Tanaka, C | 1 |
| Noguchi-Kuno, SA | 1 |
| Ichikawa, K | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Teychenné, PF | 1 |
| Ziegler, MG | 1 |
| Lake, CR | 1 |
| Enna, SJ | 2 |
| Rossor, MN | 1 |
| Perry, TL | 3 |
| Javoy-Agid, F | 4 |
| Agid, Y | 4 |
| Fibiger, HC | 1 |
| Hassler, RG | 1 |
| Scheel-Krüger, J | 1 |
| Bergmann, KJ | 1 |
| Limongi, JC | 1 |
| Lowe, YH | 1 |
| Mendoza, MR | 1 |
| Yahr, MD | 1 |
| Yoshida, M | 3 |
| Tanaka, Y | 1 |
| Mizuno, Y | 2 |
| Hadjiconstantinou, M | 1 |
| Neff, NH | 1 |
| Kurako, IuL | 1 |
| Volianskiĭ, VE | 1 |
| Colucci d'Amato, C | 1 |
| Puccini, A | 1 |
| Cristillo, A | 1 |
| Vizioli, R | 1 |
| Meldrum, B | 1 |
| Kuroda, H | 2 |
| Ferraro, TN | 1 |
| Manyam, BV | 3 |
| Hare, TA | 2 |
| Barnes, CD | 1 |
| Barbosa, ER | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| de Assis, JL | 1 |
| Christensen, SE | 1 |
| Dupont, E | 1 |
| Mondrup, K | 1 |
| Olivarius, BF | 1 |
| Orskov, H | 1 |
| Tremblay, RD | 1 |
| Manyam, NV | 1 |
| Katz, L | 1 |
| Gerber, JC | 1 |
| Grossman, MH | 1 |
| Lloyd, KG | 6 |
| Marsden, CD | 2 |
| Sheehy, MP | 1 |
| Ruberg, M | 2 |
| Taquet, H | 1 |
| Bokobza, B | 1 |
| Gaspar, P | 1 |
| Berger, B | 1 |
| N'Guyen-Legros, J | 1 |
| Alvarez, C | 1 |
| Gray, F | 1 |
| de Jong, PJ | 1 |
| Lakke, JP | 1 |
| Teelken, AW | 1 |
| Schultz, W | 1 |
| Cheng, JT | 1 |
| Schallert, T | 1 |
| De Ryck, M | 1 |
| Teitelbaum, P | 1 |
| Nakamura, S | 1 |
| Kameyama, M | 1 |
| Ogawa, N | 1 |
| Yamawaki, Y | 1 |
| Nukina, I | 1 |
| Ofuji, T | 1 |
| Yamamoto, M | 1 |
| Otsuki, S | 1 |
| Abbott, RJ | 2 |
| Pye, IF | 2 |
| Nahorski, SR | 2 |
| Keidan, J | 1 |
| Lesný, I | 1 |
| Levy, R | 1 |
| Herrero, MT | 2 |
| Villares, J | 1 |
| Faucheux, B | 1 |
| Guridi, J | 2 |
| Guillen, J | 1 |
| Luquin, MR | 3 |
| Obeso, JA | 3 |
| Espino, A | 1 |
| Llorens, J | 1 |
| Calopa, M | 1 |
| Bartrons, R | 1 |
| Rodriguez-Farré, E | 1 |
| Ambrosio, S | 1 |
| Iacono, RP | 1 |
| Lonser, R | 1 |
| Morenski, JD | 1 |
| Defazio, G | 1 |
| Dal Toso, R | 1 |
| Benvegnù, D | 1 |
| Minozzi, MC | 1 |
| Cananzi, AR | 1 |
| Leon, A | 1 |
| Gunne, LM | 2 |
| Andrén, PE | 2 |
| Timmerman, W | 1 |
| Mattammal, MB | 1 |
| Haring, JH | 1 |
| Chung, HD | 1 |
| Raghu, G | 1 |
| Strong, R | 1 |
| Maneuf, YP | 1 |
| Duty, S | 1 |
| Hille, CJ | 1 |
| Crossman, AR | 3 |
| Brotchie, JM | 2 |
| Hardman, CD | 1 |
| McRitchie, DA | 1 |
| Halliday, GM | 1 |
| Cartwright, HR | 1 |
| Morris, JG | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Vargas, C | 1 |
| Gómez, P | 1 |
| Navarro, JA | 1 |
| Benito-León, J | 1 |
| Ortí-Pareja, M | 1 |
| Gasalla, T | 1 |
| Cisneros, E | 1 |
| Arenas, J | 1 |
| Gerlach, M | 1 |
| Desser, H | 1 |
| Youdim, MB | 1 |
| Riederer, P | 1 |
| Chaná, P | 1 |
| de Marinis, A | 1 |
| Barrientos, N | 1 |
| Volpi, R | 2 |
| Chiodera, P | 2 |
| Caffarra, P | 2 |
| Scaglioni, A | 2 |
| Saccani, A | 1 |
| Coiro, V | 2 |
| Fredholm, BB | 1 |
| Svenningsson, P | 1 |
| Averbuch-Heller, L | 1 |
| Stahl, JS | 1 |
| Hlavin, ML | 1 |
| Leigh, RJ | 1 |
| Gubitz, AK | 1 |
| Freeman, TC | 1 |
| Dixon, AK | 1 |
| Rada, P | 1 |
| Tucci, S | 1 |
| Teneud, L | 1 |
| Paez, X | 1 |
| Perez, J | 1 |
| Alba, G | 1 |
| García, Y | 1 |
| Sacchettoni, S | 1 |
| del Corral, J | 1 |
| Hernandez, L | 1 |
| Grondin, R | 1 |
| Hadj Tahar, A | 1 |
| Doan, VD | 1 |
| Ladure, P | 1 |
| Bédard, PJ | 1 |
| Moy, LY | 1 |
| Marjama-Lyons, J | 1 |
| Koller, W | 1 |
| Hayes, J | 1 |
| Tipton, KF | 1 |
| Corte, LD | 1 |
| Hornykiewicz, O | 5 |
| Shimamoto, H | 1 |
| Takasaki, K | 1 |
| Shigemori, M | 1 |
| Imaizumi, T | 1 |
| Ayabe, M | 1 |
| Shoji, H | 1 |
| Sieradzan, KA | 1 |
| Fox, SH | 1 |
| Hill, M | 1 |
| Dick, JP | 1 |
| Gao, HM | 1 |
| Liu, B | 1 |
| Bourne, JA | 1 |
| Dostrovsky, JO | 1 |
| Hutchison, WD | 1 |
| Lozano, AM | 1 |
| Gramsbergen, JB | 1 |
| Sandberg, M | 1 |
| Møller Dall, A | 1 |
| Kornblit, B | 1 |
| Zimmer, J | 1 |
| Bacci, JJ | 1 |
| McGeer, PL | 1 |
| McGeer, EG | 2 |
| Fahn, S | 2 |
| Curzon, G | 1 |
| Rinne, UK | 3 |
| Toru, M | 1 |
| Costentin, J | 1 |
| Purdy, A | 1 |
| Hahn, A | 1 |
| Barnett, HJ | 1 |
| Bratty, P | 1 |
| Ahmad, D | 1 |
| Bartholini, G | 2 |
| Bowen, DM | 1 |
| Davison, AN | 1 |
| Parkes, JD | 1 |
| Hassler, R | 1 |
| Wagner, A | 1 |
| Achar, VS | 1 |
| Welch, KM | 1 |
| Chabi, E | 1 |
| Bartosh, K | 1 |
| Meyer, JS | 1 |
| Rosa, A | 1 |
| Stern, LZ | 1 |
| Wastek, GJ | 1 |
| Yamamura, HI | 2 |
| Calne, DB | 2 |
| Eisler, T | 1 |
| Dreksler, S | 1 |
| Shemen, L | 2 |
| Davidson, L | 1 |
| Spokes, EG | 1 |
| Pericić, D | 1 |
| Reisine, TD | 1 |
| Fields, JZ | 1 |
| Nutt, J | 1 |
| Williams, A | 1 |
| Plotkin, C | 1 |
| Eng, N | 1 |
| Ziegler, M | 1 |
| Hutt, CS | 1 |
| Snider, SR | 1 |
| Koskinen, V | 1 |
| Laaksonen, H | 1 |
| Lönnberg, P | 1 |
| Sonninen, V | 1 |
| Wolfarth, S | 1 |
| Iloyd, KG | 1 |
| Spehlmann, R | 1 |
| Tosca, P | 1 |
| Canevari, L | 1 |
| Di Paolo, E | 1 |
| Ferrari, R | 1 |
| Verzé, S | 1 |
| Zerbi, F | 1 |
| Dagani, F | 1 |
| Megdiatov, RS | 1 |
| Vorobeĭchik, IaM | 1 |
| Langer, LF | 1 |
| Jiménez-Castellanos, J | 1 |
| Graybiel, AM | 2 |
| Marcato, A | 1 |
| Rossi, G | 1 |
| Caffarri, G | 1 |
| Delsignore, R | 1 |
| Dambinova, SA | 1 |
| Kozlova, MV | 1 |
| Bobryshev, IuV | 1 |
| Konovalov, GV | 1 |
| Kalenchuk, VU | 1 |
| Slepko, NG | 1 |
| Koreshonkov, ON | 1 |
| Shevchenko, KA | 1 |
| Greenamyre, JT | 1 |
| O'Brien, CF | 1 |
| Snyder, SH | 1 |
| Bergeron, C | 1 |
| Steele, JC | 1 |
| McLachlan, DR | 1 |
| Hansen, S | 1 |
| Robertson, RG | 1 |
| Clarke, CA | 1 |
| Boyce, S | 1 |
| Sambrook, MA | 1 |
| Vamvakidès, A | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 1 |
| Karlsson, H | 1 |
| Ungerstedt, U | 2 |
| Lindefors, N | 1 |
| Brodin, E | 1 |
| Tossman, U | 1 |
| Segovia, J | 1 |
| Sandyk, R | 2 |
| Gillman, MA | 1 |
| Rinne, JO | 1 |
| Rinne, JK | 1 |
| Laakso, K | 1 |
| Barkhatova, VP | 1 |
| Kish, SJ | 1 |
| Rajput, A | 2 |
| Gilbert, J | 2 |
| Rozdilsky, B | 2 |
| Chang, LJ | 2 |
| Shannak, K | 2 |
| Pasik, P | 1 |
| Pasik, T | 1 |
| Perschak, H | 1 |
| Amsler, U | 1 |
| Vischer, A | 1 |
| Siegfried, J | 1 |
| Cuénod, M | 1 |
| Bonnet, AM | 1 |
| Tell, G | 1 |
| Schechter, PJ | 1 |
| Grove, J | 1 |
| Saint-Hilaire, MH | 1 |
| De Smet, Y | 1 |
| Ellenbroek, B | 1 |
| Klockgether, T | 1 |
| Turski, L | 1 |
| Schwarz, M | 1 |
| Porenta, G | 1 |
| Scatton, B | 2 |
| Zivkovic, B | 1 |
| Lheroux, A | 1 |
| Martinez Lage, JM | 1 |
| Kish, S | 1 |
| Bennett, JP | 1 |
| Ferrari, MB | 1 |
| Cruz, CJ | 1 |
| Baumeister, AA | 1 |
| Frye, GD | 1 |
| Monfort, JC | 1 |
| Hauw, JJ | 1 |
| Dubois, B | 1 |
| Soyka, D | 1 |
| Roberts, E | 1 |
| Barbeau, A | 1 |
| Sphelmann, R | 1 |
| Borromei, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroactive Steroids in Acute Ischemic Stroke: Association With Cognitive, Functional and Neurological Outcomes.[NCT02914106] | 60 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke[NCT03242304] | 40 participants (Actual) | Observational | 2016-04-01 | Completed | |||
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955] | 40 participants (Anticipated) | Observational | 2022-02-28 | Not yet recruiting | |||
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306] | 60 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
74 reviews available for gamma-aminobutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.
Topics: Astrocytes; Dopamine; gamma-Aminobutyric Acid; Humans; Hydrogen Peroxide; Monoamine Oxidase; Parkins | 2022 |
TGF-β/Smad3 Signalling Modulates GABA Neurotransmission: Implications in Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cognition; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Smad3 Prote | 2020 |
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Topics: Acetylcholine; Adenosine; Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Dopamine; gamma-Ami | 2019 |
The pathophysiology of essential tremor and Parkinson's tremor.
Topics: Animals; Electric Stimulation Therapy; Essential Tremor; gamma-Aminobutyric Acid; Humans; Movement D | 2013 |
Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.
Topics: Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Neurotensin; Parkinson Disease; Receptors | 2014 |
Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Drug Discovery; gamma-Aminobutyric | 2014 |
Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; gamma-Aminobutyric Acid; Hu | 2014 |
Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnesium; Manganese Poisoning; Par | 2015 |
The Microbiome-Gut-Brain Axis in Health and Disease.
Topics: Animals; Autistic Disorder; Brain; Cytokines; Depression; Fatty Acids, Volatile; gamma-Aminobutyric | 2017 |
Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Neurons; N | 2008 |
[Cell therapy for Parkinson disease].
Topics: Corpus Striatum; Dependovirus; Dopamine; Embryonic Stem Cells; gamma-Aminobutyric Acid; Gene Transfe | 2009 |
Basal ganglia control of substantia nigra dopaminergic neurons.
Topics: Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Models, Neurological; Nerve Net; | 2009 |
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder.
Topics: Amygdala; Animals; Brain; Brain Mapping; Cataplexy; Emotions; gamma-Aminobutyric Acid; Glutamine; Gl | 2011 |
Generating GABAergic cerebral cortical interneurons from mouse and human embryonic stem cells.
Topics: Animals; Cell Differentiation; Cell Lineage; Cerebral Cortex; Embryonic Stem Cells; gamma-Aminobutyr | 2012 |
[Progresses in the study of unbalance of basal ganglia neurotransmitters in Parkinson's disease].
Topics: Acetylcholine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neu | 2011 |
Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle.
Topics: Central Nervous System; Dementia; Evidence-Based Medicine; gamma-Aminobutyric Acid; Glutamic Acid; G | 2013 |
Gabapentin for the treatment of tremor.
Topics: Acetates; Adult; Aged; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2003 |
Frontal-striatal circuit functions: context, sequence, and consequence.
Topics: Basal Ganglia; Cognition Disorders; Corpus Striatum; Dopamine; Frontal Lobe; gamma-Aminobutyric Acid | 2003 |
Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Interneurons; Ne | 2003 |
Tremor.
Topics: Acetates; Amines; Anticonvulsants; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Diagnosis, Dif | 2003 |
Future and current surgical therapies in Parkinson's disease.
Topics: Corpus Striatum; Electric Stimulation Therapy; Fetal Tissue Transplantation; Forecasting; gamma-Amin | 2003 |
[Continuous subthalamic neurostimulation in Parkinson's disease. Indications and modalities].
Topics: Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Enkephalins; gamma-Aminobutyric Acid; | 2003 |
Essential tremor: diagnosis and treatment.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Essential Tremor; Gabapentin | 2003 |
Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.
Topics: Animals; Cell Line; Corpus Striatum; Dimerization; gamma-Aminobutyric Acid; Humans; Macromolecular S | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
Functional diversity of ventral midbrain dopamine and GABAergic neurons.
Topics: Action Potentials; Animals; Dopamine; gamma-Aminobutyric Acid; Humans; Ion Channels; Neurons; Parkin | 2004 |
GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders.
Topics: Animals; Basal Ganglia; Epilepsy; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Parkinson Diseas | 2004 |
Turning the heterogeneous into homogeneous: studies on selectively isolated GABAergic interneuron subsets.
Topics: Animals; Biomarkers; Brain; gamma-Aminobutyric Acid; Humans; Huntington Disease; Interneurons; Nerve | 2004 |
Cannabinoid control of motor function at the basal ganglia.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine; gamma-Aminobutyric | 2005 |
Striatal information signaling and integration in globus pallidus: timing matters.
Topics: Animals; Basal Ganglia; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Neostriatum; Parkinson Dis | 2005 |
Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?
Topics: Animals; Basal Ganglia Diseases; Central Nervous System; gamma-Aminobutyric Acid; Humans; Movement D | 2006 |
Cellular principles underlying normal and pathological activity in the subthalamic nucleus.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; | 2006 |
Basal ganglia mechanisms of reward-oriented eye movement.
Topics: Animals; Basal Ganglia; Behavior, Animal; Caudate Nucleus; Eye Movements; gamma-Aminobutyric Acid; H | 2007 |
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamin | 2008 |
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Corpus Striatum; Diencephalon; gam | 1984 |
Catecholamine systems of retina: a model for studying synaptic mechanisms.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Darkness; Dopamine; Ele | 1984 |
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino | 1984 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; | 1984 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
The basal ganglia in extrapyramidal dysfunction.
Topics: Basal Ganglia; Basal Ganglia Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; Feedback; gamma-Am | 1983 |
The neuropathology of GABA neurons in extrapyramidal disorders.
Topics: Basal Ganglia Diseases; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Dise | 1980 |
Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms.
Topics: Adenylyl Cyclases; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; | 1982 |
[Biochemical aspects of involuntary movements (author's transl)].
Topics: Adenosine Triphosphate; Brain; Calcium; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Movemen | 1981 |
The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease.
Topics: Animals; Basal Ganglia; Dopamine; Female; gamma-Aminobutyric Acid; Globus Pallidus; Haplorhini; Male | 1993 |
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Topics: Binding Sites; Clinical Trials as Topic; Corpus Striatum; Disease Progression; gamma-Aminobutyric Ac | 1996 |
Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum.
Topics: Acetylcholine; Animals; Behavior, Animal; Corpus Striatum; Enkephalins; gamma-Aminobutyric Acid; Gen | 1999 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona | 2000 |
Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.
Topics: Basal Ganglia; Brain Chemistry; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurons; N | 2001 |
New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia.
Topics: Adenosine; Animals; Basal Ganglia; gamma-Aminobutyric Acid; Humans; Models, Neurological; Neurotrans | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
The globus pallidus, deep brain stimulation, and Parkinson's disease.
Topics: Animals; Dopamine; Electric Stimulation Therapy; gamma-Aminobutyric Acid; Globus Pallidus; Humans; P | 2002 |
The biochemistry of the basal ganglia and Parkinson's disease.
Topics: Acetylcholine; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Norepinephrine; Parkinson D | 1977 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopam | 1978 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarbo | 1978 |
[Abnormal neurotransmission in neurological diseases (author's transl)].
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Dementia; Dopamine; Female; gamma-Ami | 1979 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
Locomotor activity and speed of movements in relation to monoamine-acting drugs.
Topics: Animals; Atropine; Basal Ganglia; Cats; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Harmalin | 1975 |
[Physiology and pharmacology of extrapyramidal tract].
Topics: Acetylcholine; Basal Ganglia; Catecholamines; Caudate Nucleus; Cerebral Cortex; Corpus Striatum; Dop | 1975 |
The pathogensis and medical treatment of extrapyramidal disease.
Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopami | 1979 |
[The role of GABA neurons in some neurological and psychiatric disorders (author's transl)].
Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Disease; Sc | 1979 |
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; C | 1976 |
[Effect of divalent cations on gamma-aminobutyric acid metabolism (review)].
Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Parkinson Disease; Recept | 1991 |
The substantia nigra and its relations with the striatum in the monkey.
Topics: Acetylcholinesterase; Afferent Pathways; Animals; Cats; Corpus Striatum; Dopamine; gamma-Aminobutyri | 1991 |
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
Topics: Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; gamma-Aminobutyric Acid; Globus Pallidus; H | 1991 |
[Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
Topics: Animals; Antiparkinson Agents; gamma-Aminobutyric Acid; Glutamates; Glycine; Humans; Parkinson Disea | 1990 |
Neuropeptides in the basal ganglia.
Topics: Animals; Basal Ganglia; Cats; Cattle; Cerebral Cortex; Cholinergic Fibers; Corpus Striatum; Dopamine | 1986 |
Chemical neurotransmission in the parkinsonian brain.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Neurons; Parkinson Disease; Synapses; Synaptic Transmission | 1987 |
[Role of catecholamines in regulating motor functions (review)].
Topics: Basal Ganglia; Brain Mapping; Catecholamines; Cerebral Cortex; Cholinergic Fibers; Dopamine; gamma-A | 1985 |
The endogenous opioid system in neurological disorders of the basal ganglia.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clonidine; Endorphins; gamma-Aminobutyric Aci | 1985 |
The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome.
Topics: Adenine Nucleotides; Animals; Central Nervous System; Child; Child, Preschool; Clonidine; Corpus Str | 1985 |
Disinhibition as an organizing principle in the nervous system. The role of gamma-aminobutyric acid.
Topics: Aminobutyrates; Animals; Astacoidea; Brain; Carboxy-Lyases; Caudate Nucleus; gamma-Aminobutyric Acid | 1974 |
The clinical physiology of side effects in long-term L-DOPA therapy.
Topics: Acetylcholine; Basal Ganglia; Brain Chemistry; Brain Stem; Creatinine; Diagnosis, Differential; Dopa | 1974 |
[Some therapeutic effects of GABA in neurology (author's transl)].
Topics: Aminobutyrates; Brain; Brain Diseases; Brain Injuries; Cerebrovascular Disorders; Coma; Epilepsy; ga | 1974 |
10 trials available for gamma-aminobutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease.
Topics: Aged; Aged, 80 and over; Animals; Cholinergic Neurons; Disease Models, Animal; Female; gamma-Aminobu | 2013 |
The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease.
Topics: Adult; Aged; Electric Stimulation Therapy; Female; gamma-Aminobutyric Acid; Globus Pallidus; Humans; | 2004 |
Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Eye Movements; Female; Gabapentin; | 2007 |
Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonist.
Topics: Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Drug Synergism; gamma-Aminobutyric A | 1984 |
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Gabapentin and motor fluctuations in Parkinson's disease.
Topics: Acetates; Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Drug Therapy, Combination | 1997 |
Different control mechanisms of growth hormone (GH) secretion between gamma-amino- and gamma-hydroxy-butyric acid: neuroendocrine evidence in Parkinson's disease.
Topics: Aged; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male; M | 1997 |
Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Biogenic Monoamines; Electromagnetic Fields; Female; gamma-Aminobutyric Aci | 2001 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, | 2001 |
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; g | 1979 |
187 other studies available for gamma-aminobutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Effects of bee venom and dopamine-loaded nanoparticles on reserpine-induced Parkinson's disease rat model.
Topics: Animals; Antiparkinson Agents; Bee Venoms; Brain-Derived Neurotrophic Factor; DNA Fragmentation; Dop | 2021 |
Acute psychosis following propofol in a patient with Parkinson disease: Effects of a γ-aminobutyric acid-dopamine imbalance.
Topics: Anesthetics, Intravenous; Dopamine; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Propofol; Ps | 2022 |
Optimization of the use of Py-Tag for next generation derivatization reagents in imaging mass spectrometry.
Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Indicators and Reagents; Mass Spectrometry; Mesylates; P | 2022 |
Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.
Topics: Brain Mapping; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Medically Unexplained Sy | 2022 |
Effect of Subthalamic Stimulation and Electrode Implantation in the Striatal Microenvironment in a Parkinson's Disease Rat Model.
Topics: Amino Acid Transport Systems; Animals; Cytokines; Deep Brain Stimulation; Electrodes; gamma-Aminobut | 2022 |
Therapeutic function of a novel rat induced pluripotent stem cell line in a 6‑OHDA‑induced rat model of Parkinson's disease.
Topics: Animals; Cell Differentiation; Dopaminergic Neurons; gamma-Aminobutyric Acid; Induced Pluripotent St | 2022 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Assessing the interaction between L-dopa and γ-transcranial alternating current stimulation effects on primary motor cortex plasticity in Parkinson's disease.
Topics: Dopamine; Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Neurona | 2023 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease.
Topics: Cell Line, Tumor; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Humans; Neuroblastoma; Ne | 2023 |
Miniature-swine iPSC-derived GABA progenitor cells function in a rat Parkinson's disease model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; GABAergic Neurons; gamma-Ami | 2023 |
Short-term plasticity of the motor cortex compensates for bradykinesia in Parkinson's disease.
Topics: Evoked Potentials, Motor; gamma-Aminobutyric Acid; Humans; Hypokinesia; Motor Cortex; Parkinson Dise | 2023 |
The α1 and γ2 subunit-containing GABA
Topics: Animals; Anxiety; Dopamine; Dorsal Raphe Nucleus; gamma-Aminobutyric Acid; Oxidopamine; Parkinson Di | 2023 |
Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Alanine Transaminase; Anim | 2020 |
Distinct gradients of various neurotransmitter markers in caudate nucleus and putamen of the human brain.
Topics: Adult; Aged; Aged, 80 and over; Aging; Biomarkers; Caudate Nucleus; Choline O-Acetyltransferase; Dop | 2020 |
GABAergic changes in the thalamocortical circuit in Parkinson's disease.
Topics: Aged; Creatine; Dopamine Agents; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectro | 2020 |
Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Animals; Astrocytes; Disease Models, Animal; Dopaminergic Neurons; Down-Reg | 2020 |
Inhibition of NADPH oxidase within midbrain periaqueductal gray decreases pain sensitivity in Parkinson's disease via GABAergic signaling pathway.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Medial Forebrain Bundle; NADPH Oxida | 2020 |
High γ-Aminobutyric Acid Content Within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients With Parkinson's Disease.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Medically Unexplained Symptoms; Parkinson | 2020 |
Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
Topics: Brain Stem; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease | 2021 |
Upper brainstem GABA levels in Parkinson's disease.
Topics: Brain Stem; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectros | 2021 |
l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2022 |
Hippocampal and Reticulo-Thalamic Parvalbumin Interneurons and Synaptic Re-Organization during Sleep Disorders in the Rat Models of Parkinson's Disease Neuropathology.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; gamma-Aminobutyric Acid; Hippocampus | 2021 |
Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; Ind | 2017 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Oxazepam-Dopamine Conjugates Increase Dopamine Delivery into Striatum of Intact Rats.
Topics: Animals; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; gamma | 2017 |
Light Therapy Promoting Dopamine Release by Stimulating Retina in Parkinson Disease-Reply.
Topics: Dopamine; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Phototherapy; Retina | 2017 |
Real-time Correction of Motion and Imager Instability Artifacts during 3D γ-Aminobutyric Acid-edited MR Spectroscopic Imaging.
Topics: Aged; Artifacts; Cognitive Dysfunction; Contrast Media; Equipment Failure; Female; gamma-Aminobutyri | 2018 |
Inhibitory motor dysfunction in parkinson's disease subtypes.
Topics: Aged; Basal Ganglia; Brain; Case-Control Studies; Female; Gait; Gait Disorders, Neurologic; gamma-Am | 2018 |
Examining alterations in GABA concentrations in the basal ganglia of patients with Parkinson's disease using MEGA-PRESS MRS.
Topics: Aged; Basal Ganglia; Female; gamma-Aminobutyric Acid; Humans; Image Processing, Computer-Assisted; M | 2018 |
Neurotransmitter activity is linked to outcome following subthalamic deep brain stimulation in Parkinson's disease.
Topics: Aged; Basal Ganglia; Deep Brain Stimulation; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutami | 2018 |
GAT-3 Dysfunction Generates Tonic Inhibition in External Globus Pallidus Neurons in Parkinsonian Rodents.
Topics: Animals; Dopamine; GABA Plasma Membrane Transport Proteins; GABAergic Neurons; gamma-Aminobutyric Ac | 2018 |
GABA and hallucinations in Parkinson disease: Who is that sitting on my chair?
Topics: gamma-Aminobutyric Acid; Hallucinations; Humans; Parkinson Disease; Posture; Sitting Position | 2018 |
Reduced occipital GABA in Parkinson disease with visual hallucinations.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Creatine; Female; gamma-Aminobutyric Acid; Gray Matter | 2018 |
Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
Topics: Acetylcholine; Animals; Brain; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Gene Knockou | 2019 |
Intervention changes acoustic peak frequency and mesolimbic neurochemistry in the Pink1-/- rat model of Parkinson disease.
Topics: Animals; Animals, Genetically Modified; Catecholamines; Disease Models, Animal; gamma-Aminobutyric A | 2019 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Bone Marrow Transplantation; Catalase; Corpus Stri | 2013 |
Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Early Diagnosis; Female; gamma-Aminobutyric Acid; | 2013 |
Protective effect of arctigenin against MPP+ and MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Brain | 2014 |
Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebral Cortex; Chromatography, High Pressure Liquid; Chro | 2014 |
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Globus Pallidus; Male; Microdialysis; N-Me | 2015 |
Glutamate and GABA concentration changes in the globus pallidus internus of Parkinson's patients during performance of implicit and declarative memory tasks: a report of two subjects.
Topics: Acoustic Stimulation; Deep Brain Stimulation; Female; gamma-Aminobutyric Acid; Globus Pallidus; Glut | 2015 |
Striatal and thalamic GABA level concentrations play differential roles for the modulation of response selection processes by proprioceptive information.
Topics: Aged; Attention; Conflict, Psychological; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonanc | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Stri | 2016 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Glio | 2016 |
Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease.
Topics: Animals; Cell Differentiation; Cell Line; Clozapine; Disease Models, Animal; Dopaminergic Neurons; D | 2016 |
Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Hypokinesia; Mice, Tra | 2016 |
Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Dopamine; Dopaminergic Neurons; GABAergic Neu | 2016 |
Blunted mGluR Activation Disinhibits Striatopallidal Transmission in Parkinsonian Mice.
Topics: Animals; Astrocytes; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic A | 2016 |
Impact of the Chronic Omega-3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6-Hydroxydopamine in Rats.
Topics: Animals; Apomorphine; Biogenic Monoamines; Brain; Dietary Supplements; Disease Models, Animal; Fatty | 2017 |
A Subpopulation of Dopaminergic Neurons Coexpresses Serotonin in Ventral Mesencephalic Cultures But Not After Intrastriatal Transplantation in a Rat Model of Parkinson's Disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Count; Cells, Cultured; Disease Models, Animal; Dop | 2017 |
Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Cerebral Cortex; Female; gamma-Aminobutyric Acid; | 2017 |
GABAergic mechanism mediated via D receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study.
Topics: Animals; Benzazepines; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Extracel | 2008 |
Gabapentin-Induced myoclonus: case report.
Topics: Aged, 80 and over; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2008 |
Bilateral ballism induced by gabapentin in idiopatic Parkinson's disease.
Topics: Aged, 80 and over; Amines; Anticonvulsants; Back Pain; Comorbidity; Cyclohexanecarboxylic Acids; Dys | 2009 |
In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Frequency-selectivity of a thalamocortical relay neuron during Parkinson's disease and deep brain stimulation: a computational study.
Topics: Algorithms; Brain; Calcium; Cerebral Cortex; Computer Simulation; Deep Brain Stimulation; Dendrites; | 2009 |
Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons.
Topics: Animals; Cell Count; Cells, Cultured; Corpus Striatum; Cytoprotection; Dendrites; Disease Models, An | 2010 |
Electro-acupuncture stimulation acts on the basal ganglia output pathway to ameliorate motor impairment in Parkinsonian model rats.
Topics: Acupuncture Therapy; Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dopamine; Elec | 2010 |
Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Aging; Autoradiography; Brain Chemistry; gamma-Aminobutyric Acid; Gl | 2010 |
[The protective effect of nicotine on dopaminergic neuron of Parkinson's disease mice].
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Dopaminergic Neurons; Female; gamma-Aminobutyric A | 2007 |
[Effect of stimulation of STN on the firing activities of the SNr neurons in rats].
Topics: Action Potentials; Animals; Electric Stimulation; Electrophoresis; gamma-Aminobutyric Acid; Glutamic | 2009 |
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus.
Topics: Aged; Antiparkinson Agents; Cyclic GMP; Deep Brain Stimulation; gamma-Aminobutyric Acid; Humans; Lev | 2011 |
Pathophysiology of freezing of gait and some possible treatments for it.
Topics: Amines; Cyclohexanecarboxylic Acids; Dopamine; Excitatory Amino Acid Antagonists; Gabapentin; Gait; | 2012 |
Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS.
Topics: Case-Control Studies; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonan | 2012 |
Imidazoleacetic acid-ribotide in the rodent striatum: a putative neurochemical link between motor and autonomic deficits in Parkinson's disease.
Topics: Animals; Autonomic Nervous System; Basal Ganglia; Calbindin 1; Calbindins; Electric Stimulation; Evo | 2012 |
Inhibition of glutamate and acetylcholine release in behavioral improvement induced by electroacupuncture in parkinsonian rats.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Electroacupuncture; gamma-Aminobutyric Acid; Glut | 2012 |
Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study.
Topics: Aged; Cerebellum; Essential Tremor; Female; Flumazenil; gamma-Aminobutyric Acid; Humans; Image Proce | 2012 |
Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; M | 2013 |
Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.
Topics: Animals; Basal Ganglia; Cognition; Dopamine Agonists; Dopaminergic Neurons; Dose-Response Relationsh | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine; Animals; Calcium Signaling; Dopamine Agonists; Do | 2002 |
Alpha2-adrenoceptor activation increases a cationic conductance and spontaneous GABAergic synaptic activity in dopaminergic neurones of the rat substantia nigra.
Topics: Action Potentials; Adaptation, Physiological; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonist | 2002 |
Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Topics: Animals; Dendrites; Dopamine; Dopamine Antagonists; Drug Synergism; Extracellular Space; GABA Antago | 2003 |
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.
Topics: Adrenergic Uptake Inhibitors; Aminobutyrates; Animals; Corpus Striatum; Disease Models, Animal; Elec | 2003 |
Serotonergic regulation of the GABAergic transmission in the rat basal ganglia.
Topics: 5,7-Dihydroxytryptamine; Animals; Basal Ganglia; Extracellular Fluid; Female; gamma-Aminobutyric Aci | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; | 2003 |
[Experience in the use of gamma-aminobutyric acid in our clinic].
Topics: Ambulatory Care Facilities; Amino Acids; Antifibrinolytic Agents; Cerebrovascular Disorders; gamma-A | 1962 |
Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Corpus Striatum; gamma- | 2003 |
Evidence for a role of basal ganglia in the regulation of rapid eye movement sleep by electrical and chemical stimulation for the pedunculopontine tegmental nucleus and the substantia nigra pars reticulata in decerebrate cats.
Topics: Animals; Basal Ganglia; Bicuculline; Cats; Decerebrate State; Electric Stimulation; GABA Agonists; G | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic A | 2004 |
The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Topics: Animals; beta-Alanine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response R | 2004 |
GABAergic interneurons in human subthalamic nucleus.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Basal Ganglia; Calcium-Binding Proteins; Dee | 2005 |
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Topics: alpha-Synuclein; Animals; Astrocytes; Brain; Cells, Cultured; Dinoprostone; Dopamine; Embryo, Mammal | 2005 |
Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Evoked Potentials; Excitatory Amino Acid An | 2005 |
Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Electric Stimulation; Fema | 2005 |
Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations.
Topics: Aspartic Acid; Feasibility Studies; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Humans; Mag | 2006 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatog | 2006 |
Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery.
Topics: Deep Brain Stimulation; Dexmedetomidine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; | 2006 |
Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Chromatography, High Press | 2006 |
Deep brain stimulation in Parkinson's disease patients: biochemical evidence.
Topics: Aged; Biomarkers; Cyclic GMP; Deep Brain Stimulation; Extracellular Space; Female; gamma-Aminobutyri | 2006 |
Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: Relevance to Parkinson's disease.
Topics: Animals; Apoptosis; Biopterins; Caspase 3; Cell Count; Cells, Cultured; Coloring Agents; Cytochromes | 2007 |
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease.
Topics: Animals; Brain Chemistry; Cell Count; Cell Membrane; Cells, Cultured; Chromatography, High Pressure | 2007 |
Dyskinesia induced by gabapentin in idiopathic Parkinson's disease.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesia, Drug-Induced; Gabapenti | 2007 |
Metabotropic glutamate receptors.
Topics: Animals; Antipsychotic Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ligands; Models, Biol | 2007 |
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Ac | 2007 |
Zolpidem modulates GABA(A) receptor function in subthalamic nucleus.
Topics: Animals; Flumazenil; GABA Agonists; GABA Modulators; GABA-A Receptor Agonists; GABA-A Receptor Antag | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-In | 2007 |
Effects of GABA and GABA receptor inhibition on differentiation of mesencephalic precursors into dopaminergic neurons in vitro.
Topics: Animals; Apoptosis; Bicuculline; Cell Culture Techniques; Cell Differentiation; Cell- and Tissue-Bas | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatogra | 2007 |
[Gene therapy for Parkinson disease].
Topics: Clinical Trials, Phase I as Topic; Dopamine; gamma-Aminobutyric Acid; Genetic Therapy; Genetic Vecto | 2007 |
Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.
Topics: Animals; Animals, Newborn; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Excitatory Ami | 2008 |
Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Corpus Striatum; Dopam | 1984 |
[Neurochemical pathology of GABAergic and cholinergic systems in Parkinson disease: an autopsy study].
Topics: Acetylcholine; Adult; Aged; Brain; Choline O-Acetyltransferase; Female; gamma-Aminobutyric Acid; Glu | 1984 |
Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Female; gamma-Aminobutyric Acid; Humans; | 1982 |
Neurotransmitters and CNS disease. Dementia.
Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Dopa | 1982 |
Striatal GABAergic neuronal activity is not reduced in Parkinson's disease.
Topics: Amino Acids; Animals; Carboxy-Lyases; Corpus Striatum; gamma-Aminobutyric Acid; Glutamate Decarboxyl | 1983 |
Chairman's introduction: role of the pallidum and its transmitters in the therapy of parkinsonian rigidity and akinesia.
Topics: Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Neurotransmit | 1984 |
[Functional and pathophysiological aspects of the basal ganglia].
Topics: Adolescent; Basal Ganglia; Child; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamates; Gl | 1984 |
[GABA, glutamate, aspartate, glycine, and taurine contents in spinocerebellar degeneration and parkinsonism].
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellar Ataxia; Chromatography, High Pr | 1984 |
Gamma-aminobutyric acid (GABA) in cerebrospinal fluid.
Topics: Adult; Behcet Syndrome; Cerebellar Diseases; Cerebral Infarction; Dementia; Female; gamma-Aminobutyr | 1983 |
Further characterization of in vitro conditions appropriate for GABA determination in human CSF: impact of acid deproteinization and freeze/thaw.
Topics: Adult; Aged; Benzenesulfonates; Drug Stability; Female; Freezing; gamma-Aminobutyric Acid; Humans; H | 1983 |
[Huntington chorea: report of 16 cases].
Topics: Adult; Aged; Brain Diseases; Chlorpromazine; Dementia; Diagnosis, Differential; Female; gamma-Aminob | 1983 |
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid.
Topics: Adult; Aged; Alzheimer Disease; Atrophy; Brain Diseases; Female; gamma-Aminobutyric Acid; Humans; Hu | 1984 |
Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid.
Topics: Adult; Age Factors; Aged; Cerebellar Ataxia; Dementia; Epilepsy; gamma-Aminobutyric Acid; Humans; Hu | 1984 |
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.
Topics: Brain Chemistry; Cerebellar Diseases; Creatine Kinase; Dementia; Diet; Encephalitis; Epilepsy; gamma | 1980 |
Biochemical neuropathology of Parkinson's disease.
Topics: Acetylcholine; Brain; Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Humans; Hypothalamus; Limb | 1984 |
CSF GABA levels in Parkinson's disease.
Topics: Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Parkinson Disease; Probenecid | 1984 |
Galloping induced by pontine tegmentum damage in rats: a form of "Parkinsonian festination" not blocked by haloperidol.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Locomotion; Male; Motor Activ | 1981 |
Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases.
Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Nervous System Diseases; Par | 1982 |
CSF and plasma GABA levels in Parkinson's disease.
Topics: Adult; Aged; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Parkinson Disease | 1982 |
Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Topics: Aged; Carbidopa; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Effect of freezing on gamma-aminobutyric acid levels in human cerebrospinal fluid.
Topics: Adult; Freezing; gamma-Aminobutyric Acid; Humans; Middle Aged; Nervous System Diseases; Parkinson Di | 1981 |
The subcortical regulatory motor system in the development and its disorders.
Topics: Cerebellum; Child; Child, Preschool; Corpus Striatum; gamma-Aminobutyric Acid; Humans; Infant; Infan | 1980 |
Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Denervation; gamma-Aminobutyric Acid; Glutamate D | 1995 |
Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; gam | 1995 |
Movement disorders stereotactic surgery for Parkinson's disease.
Topics: Brain Mapping; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Neural Inhibition; Neural Pathways; | 1994 |
Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture.
Topics: Aged; Animals; Antibodies; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cells, Cult | 1994 |
[What is the connection between Parkinson disease and tardive dyskinesia?].
Topics: Animals; Antipsychotic Agents; Deoxyglucose; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hapl | 1994 |
An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.
Topics: Animals; Brain Chemistry; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyri | 1993 |
Dopaminergic receptor agents and the basal ganglia: pharmacological properties and interactions with the GABA-ergic system.
Topics: Animals; Basal Ganglia; Behavior, Animal; Dopamine Agents; gamma-Aminobutyric Acid; Humans; Parkinso | 1993 |
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Culture Techniques; Dopamine; Dopamine Uptake Inhibitors; g | 1995 |
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzopyrans; Cromakalim; Diazoxide; Disease Mode | 1996 |
Substantia nigra pars reticulata neurons in Parkinson's disease.
Topics: Age of Onset; Aged; Aged, 80 and over; Cause of Death; Female; gamma-Aminobutyric Acid; Humans; Immu | 1996 |
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Asparagine; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutam | 1996 |
Striatal adenosine A2A receptors--where are they? What do they do?
Topics: Acetylcholine; Corpus Striatum; Electric Stimulation; gamma-Aminobutyric Acid; Humans; Neurons; Park | 1998 |
Square-wave jerks induced by pallidotomy in parkinsonian patients.
Topics: Adult; Aged; Female; Fixation, Ocular; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Male; Neura | 1999 |
Monitoring gamma-aminobutyric acid in human brain and plasma microdialysates using micellar electrokinetic chromatography and laser-induced fluorescence detection.
Topics: Brain; Chromatography, Micellar Electrokinetic Capillary; Electric Stimulation; Electrophoresis, Cap | 1999 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents | 2000 |
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox | 2000 |
Complexities in the neurotoxic actions of 6-hydroxydopamine in relation to the cytoprotective properties of taurine.
Topics: Aconitate Hydratase; Adrenergic Agents; Animals; Dopamine; Extracellular Space; gamma-Aminobutyric A | 2001 |
Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons.
Topics: Animals; Coculture Techniques; Dopamine; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; | 2002 |
Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin.
Topics: Animals; Animals, Newborn; Biopterins; Buthionine Sulfoximine; Coculture Techniques; Dopamine; Enzym | 2002 |
Effects of intralaminar thalamic nuclei lesion on glutamic acid decarboxylase (GAD65 and GAD67) and cytochrome oxidase subunit I mRNA expression in the basal ganglia of the rat.
Topics: Animals; Basal Ganglia; Denervation; Down-Regulation; Electron Transport Complex IV; Entopeduncular | 2002 |
Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.
Topics: Acetylcholine; Acetylcholinesterase; Adolescent; Adult; Age Factors; Aged; Aminobutyrates; Brain; Ca | 1976 |
Biochemistry of the basal ganglia.
Topics: Adult; Animals; Basal Ganglia; Cats; Cerebellar Cortex; Cerebral Cortex; Dogs; Dopamine beta-Hydroxy | 1976 |
Neurohumoral interactions and basal ganglia function and dysfunction.
Topics: Acetylcholine; Basal Ganglia; Caudate Nucleus; Dopamine; Feedback; gamma-Aminobutyric Acid; Humans; | 1976 |
[Basal ganglia lesions and neurotransmitters].
Topics: Acetylcholine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease | 1978 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induce | 1979 |
Letter: Extrapyramidal diseases and dementia.
Topics: Aged; Brain; Dementia; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Parkinson Disease | 1975 |
Success and problems of long-term levodopa therapy in Parkinson's disease.
Topics: Brain; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation; gamma-Aminobuty | 1977 |
Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.
Topics: Aminobutyrates; Cerebrovascular Disorders; Dementia; Epilepsy, Post-Traumatic; Epilepsy, Temporal Lo | 1976 |
[Neurology in 1977].
Topics: Bromocriptine; Defense Mechanisms; Dopamine; Facial Paralysis; gamma-Aminobutyric Acid; Hemiplegia; | 1977 |
Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Aminobutyrates; Child; Dementia; gamma-Aminobutyric Acid | 1977 |
Sodium-independent, high-affinity binding of [3H]gamma-aminobutyric acid in human neurological disorders.
Topics: Binding, Competitive; Brain; Cerebellar Cortex; gamma-Aminobutyric Acid; Humans; Huntington Disease; | 1979 |
GABA in Huntington's chorea, Parkinsonism and schizophrenia.
Topics: Animals; Body Temperature; Brain; Carboxy-Lyases; Death, Sudden; gamma-Aminobutyric Acid; Glutamate | 1979 |
Neurotransmitter receptor alterations in Parkinson's disease.
Topics: Aged; Brain; Caudate Nucleus; Choline O-Acetyltransferase; gamma-Aminobutyric Acid; Globus Pallidus; | 1977 |
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric | 1977 |
GABA receptor binding in the parkinsonian brain.
Topics: Aged; Aminobutyrates; Brain; Cerebellar Cortex; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Hu | 1978 |
Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid [3H]GABA binding in the human brain: alterations in Parkinson's disease.
Topics: Adult; Aged; Aminobutyrates; Brain; Brain Chemistry; Cerebellar Cortex; Female; gamma-Aminobutyric A | 1977 |
CNS compensation to dopamine neuron loss in Parkinson's disease.
Topics: Acetylcholine; Aminobutyrates; Brain; Choline O-Acetyltransferase; Corpus Striatum; Dopa Decarboxyla | 1977 |
The effects of acetylcholine and dopamine on the caudate nucleus depleted of biogenic amines.
Topics: Acetylcholine; Action Potentials; Animals; Biogenic Amines; Cats; Caudate Nucleus; Depression, Chemi | 1975 |
Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy.
Topics: Age Factors; Aged; Aged, 80 and over; Dementia; Female; gamma-Aminobutyric Acid; Glutamates; Glutami | 1992 |
Dopamine and basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric A | 1991 |
Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in Parkinson's disease.
Topics: Aged; Baclofen; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male; Middle Aged; Parkinson Diseas | 1991 |
[Neurotropic effect of endogenous peptides having a therapeutic effect on patients with Parkinson's disease].
Topics: Animals; Blood Transfusion, Autologous; Cells, Cultured; Chromatography, High Pressure Liquid; Elect | 1991 |
Parkinson's disease. Fresh factors to consider.
Topics: Animals; DNA; Dopamine; gamma-Aminobutyric Acid; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue | 1991 |
Brain amino acid contents are dissimilar in sporadic and Guamanian amyotrophic lateral sclerosis.
Topics: Aged; Amino Acids; Amyotrophic Lateral Sclerosis; Brain; Female; gamma-Aminobutyric Acid; Glutamates | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Str | 1990 |
Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients.
Topics: Aged; Amino Acids; Biogenic Monoamines; Brain; Chromatography, High Pressure Liquid; Dialysis; Femal | 1990 |
Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Hydroxydopamines; Male; Neurokinin A; O | 1989 |
Opioid hypofunction in Parkinson's disease.
Topics: Acetylcholine; Animals; Brain; Dopamine; Endorphins; gamma-Aminobutyric Acid; Neurotransmitter Agent | 1985 |
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Topics: Brain Chemistry; Corpus Striatum; Dopamine; Ethanolamines; gamma-Aminobutyric Acid; Glutamate Decarb | 1986 |
Ultrastructural chemoanatomy of the basal ganglia: an overview.
Topics: Axons; Basal Ganglia; Corpus Striatum; Dendrites; Dopamine; Enkephalins; gamma-Aminobutyric Acid; Gl | 1987 |
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Ethanolamine; Ethanolamines; Female; gamma-Aminobutyric Aci | 1987 |
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea.
Topics: Adult; Aged; Carnosine; Dipeptides; Female; Friedreich Ataxia; gamma-Aminobutyric Acid; Humans; Hunt | 1987 |
Distinct sites of functional interaction between dopamine, acetylcholine and gamma-aminobutyrate within the neostriatum: an electromyographic study in rats.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Electromyography; gamma-Aminobutyric Acid; Male; | 1986 |
A computer model of neuronal pathways in the basal ganglia.
Topics: Acetylcholine; Basal Ganglia; Computers; Dopamine; Feedback; gamma-Aminobutyric Acid; Humans; Membra | 1986 |
GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Cholinergic Fibers; Corpus Striatum; Dopamine; Extrapy | 1987 |
Progabide in Parkinson's disease.
Topics: gamma-Aminobutyric Acid; Humans; Parkinson Disease | 1987 |
GABA-dopamine relationship in Parkinson's disease striatum.
Topics: Aged; Caudate Nucleus; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Neurons; Parkinso | 1987 |
GABA-mimetic drugs enhance apomorphine-induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: implications for the therapy of Parkinson's disease.
Topics: Alkynes; Aminocaproates; Animals; Antiparkinson Agents; Apomorphine; Drug Synergism; gamma-Aminobuty | 1987 |
Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index.
Topics: Age Factors; Aged; Brain; Caudate Nucleus; Cerebral Cortex; Corpus Striatum; Female; gamma-Aminobuty | 1985 |
[Syndrome involving the extrapyramidal motor systems and their drug treatment].
Topics: Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dihydroxyphenylalanine; gamma-Aminobutyric | 1974 |
The susceptibility to acetylcholine and dopamine in the caudate nucleus of cats with chronic nigrostriatal lesions.
Topics: Acetylcholine; Animals; Cats; Caudate Nucleus; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; G | 1974 |